Raju Mohan - Apr 5, 2023 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
Chief Executive Officer, Director
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Stock symbol
VTYX
Transactions as of
Apr 5, 2023
Transactions value $
-$612,401
Form type
4
Date filed
4/7/2023, 03:47 PM
Previous filing
Jan 18, 2023
Next filing
Apr 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Sale -$301K -10.2K -0.63% $29.61 1.59M Apr 5, 2023 Direct F1, F2
transaction VTYX Common Stock Sale -$93.5K -3.07K -0.19% $30.49 1.59M Apr 5, 2023 Direct F1, F3
transaction VTYX Common Stock Sale -$218K -7.52K -0.47% $29.01 1.58M Apr 6, 2023 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2022.
F2 Represents the weighted average share price of an aggregate total of 10,165 shares sold in the price range of $29.00 to $29.9994. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 3,065 shares sold in the price range of $30.0008 to $30.835. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Represents the weighted average share price of an aggregate total of 7,515 shares sold in the price range of $29.00 to $29.085. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.